Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease
In March of 2018, the National Kidney Foundation, in collaboration with the US Food and Drug Administration and the European Medicines Agency, sponsored a workshop in which surrogate endpoints other than currently established event‐time endpoints for clinical trials in chronic kidney disease (CKD) w...
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
Wiley
2019
|